NEW YORK, March 23, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com takes a closer look at four equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS). On Tuesday, March 21st, 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about these stocks by downloading their free report at:
On Wednesday, shares in Richmond, California headquartered Sangamo Therapeutics Inc. recorded a trading volume of 622,069 shares. The stock ended the session 1.23% lower at $4.00. The Company's shares have gained 1.27% in the last one month, 15.94% over the previous three months, and 31.15% on an YTD basis. The stock is trading 0.05% above its 50-day moving average. Moreover, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have a Relative Strength Index (RSI) of 45.10.
On March 01st, 2017, Sangamo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-913, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type-II, a rare lysosomal storage disorder. The Company has also submitted an application to the FDA for rare pediatric disease designation for SB-913. The free research report on SGMO is available at:
Waltham, Massachusetts headquartered Eyegate Pharmaceuticals Inc.'s stock closed the day 3.81% lower at $2.27 with a total trading volume of 148,838 shares. The Company's shares have surged 27.53% in the previous three months and 39.26% since the start of this year. The stock is trading 9.93% and 14.71% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Eyegate Pharma, which focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye, have an RSI of 45.84.
On March 13th, 2017, Eyegate announced the appointment of two leading ophthalmology experts, Daniel S. Durrie, M.D. and Randall J. Olson, M.D., to its Scientific Advisory Board (SAB). Drs. Durrie and Olson will work together with the other members of EyeGate's SAB to provide the Company strategic guidance and support the continued development of its ophthalmic platforms, EGP-437 and EyeGate OBG. The complimentary report on EYEG can be downloaded at:
Shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 431,519 shares. The stock ended yesterday's trading session 0.20% higher at $0.70. The Company's shares are trading below their 50-day moving average by 13.34%. Furthermore, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have an RSI of 32.68.
On March 02nd, 2017, Synthetic Biologics reported financial results for the year ended December 31st, 2016. General and administrative expenses were $10.1 million in 2016 compared to $8.1 million in 2015. R&D expenses decreased to $29.1 million during the year from $32.9 million in 2015. Other income was $11.4 million compared to other expense of $3.8 million during the same period a year ago. Visit us today and download our complete research report on SYN for free at:
San Diego, California headquartered Regulus Therapeutics Inc.'s stock finished Wednesday's session 4.17% higher at $1.25 with a total trading volume of 869,258 shares. The Company's shares have advanced 13.64% in the last one month. The stock is trading below its 50-day moving average by 18.55%. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 43.38.
On March 06th, 2017, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $8 a share to $6 a share. Get free access to your technical report on RGLS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA